In renal carcinoma cells, the matrix metalloproteinase (MMP) inhibitor GM 6001 diminishes the tyrosine phosphorylation of the EGFR induced by PAR1, pointing to a critical involvement of metalloproteinase activity in the PAR1-mediated transactivation of the EGFR in renal carcinoma cells [111]. The gene discussed is F2R; the disease is renal carcinoma.